Is HURA or ARVN more profitable?

Arvinas has a net margin of 2.94% compared to TuHURA Biosciences' net margin of 0.00%. Arvinas' return on equity of 1.91% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Arvinas 2.94% 1.91% 1.29%

Does the media refer more to HURA or ARVN?

In the previous week, TuHURA Biosciences had 14 more articles in the media than Arvinas. MarketBeat recorded 17 mentions for TuHURA Biosciences and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat TuHURA Biosciences' score of 0.56 indicating that Arvinas is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Arvinas 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALT or HURA?

In the previous week, TuHURA Biosciences had 2 more articles in the media than Altimmune. MarketBeat recorded 17 mentions for TuHURA Biosciences and 15 mentions for Altimmune. Altimmune's average media sentiment score of 0.80 beat TuHURA Biosciences' score of 0.56 indicating that Altimmune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, EIKN or HURA?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eikon Therapeutics N/A N/A -$324.25M -$4.09 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A

Is EIKN or HURA more profitable?

Eikon Therapeutics' return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Eikon Therapeutics N/A N/A N/A TuHURA Biosciences N/A -156.47% -106.98%

Does the media prefer EIKN or HURA?

In the previous week, TuHURA Biosciences had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Eikon Therapeutics. TuHURA Biosciences' average media sentiment score of 0.56 beat Eikon Therapeutics' score of -0.13 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eikon Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral TuHURA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, HURA or ARTV?

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.54 N/A Artiva Biotherapeutics N/A N/A -$83.86M -$3.30 N/A

Is HURA or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.47% -106.98% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media refer more to HURA or ARTV?

In the previous week, TuHURA Biosciences had 12 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Artiva Biotherapeutics. TuHURA Biosciences' average media sentiment score of 0.56 beat Artiva Biotherapeutics' score of 0.42 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HURA or PRME?

In the previous week, TuHURA Biosciences had 12 more articles in the media than Prime Medicine. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat TuHURA Biosciences' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TuHURA Biosciences (HURA) Competitors

$2.15 +0.16 (+7.75%)

As of 03:44 PM Eastern

Compare

HURA vs. ARVN, ALT, EIKN, ARTV, and PRME

Should you buy TuHURA Biosciences stock or one of its competitors? TuHURA Biosciences's main competitors and comparable companies include Arvinas (ARVN), Altimmune (ALT), Eikon Therapeutics (EIKN), Artiva Biotherapeutics (ARTV), and Prime Medicine (PRME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TuHURA Biosciences compare to Arvinas?

TuHURA Biosciences (NASDAQ:HURA) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

TuHURA Biosciences has higher earnings, but lower revenue than Arvinas. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Arvinas	$316.70M	1.89	-$80.80M	$0.10	92.85

Arvinas has a net margin of 2.94% compared to TuHURA Biosciences' net margin of 0.00%. Arvinas' return on equity of 1.91% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Arvinas	2.94%	1.91%	1.29%

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 7.3% of Arvinas shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Arvinas has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market.

In the previous week, TuHURA Biosciences had 14 more articles in the media than Arvinas. MarketBeat recorded 17 mentions for TuHURA Biosciences and 3 mentions for Arvinas. Arvinas' average media sentiment score of 0.94 beat TuHURA Biosciences' score of 0.56 indicating that Arvinas is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arvinas	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences presently has a consensus price target of $9.00, indicating a potential upside of 317.63%. Arvinas has a consensus price target of $14.17, indicating a potential upside of 52.58%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arvinas	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

Summary

Arvinas beats TuHURA Biosciences on 11 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

78.1% of Altimmune shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TuHURA Biosciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-31.41%	-26.96%
TuHURA Biosciences	N/A	-156.47%	-106.98%

In the previous week, TuHURA Biosciences had 2 more articles in the media than Altimmune. MarketBeat recorded 17 mentions for TuHURA Biosciences and 15 mentions for Altimmune. Altimmune's average media sentiment score of 0.80 beat TuHURA Biosciences' score of 0.56 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$31K	19,608.67	-$88.09M	-$0.78	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Altimmune presently has a consensus target price of $14.33, suggesting a potential upside of 358.67%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 317.63%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

Summary

Altimmune beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Eikon Therapeutics?

Eikon Therapeutics (NASDAQ:EIKN) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Eikon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eikon Therapeutics	N/A	N/A	-$324.25M	-$4.09	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

Eikon Therapeutics presently has a consensus target price of $25.00, suggesting a potential upside of 120.67%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 317.63%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Eikon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eikon Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

0.6% of TuHURA Biosciences shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Eikon Therapeutics' return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eikon Therapeutics	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.47%	-106.98%

In the previous week, TuHURA Biosciences had 12 more articles in the media than Eikon Therapeutics. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Eikon Therapeutics. TuHURA Biosciences' average media sentiment score of 0.56 beat Eikon Therapeutics' score of -0.13 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eikon Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
TuHURA Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TuHURA Biosciences beats Eikon Therapeutics on 8 of the 11 factors compared between the two stocks.

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

TuHURA Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 317.63%. Artiva Biotherapeutics has a consensus price target of $39.00, suggesting a potential upside of 236.93%. Given TuHURA Biosciences' higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

TuHURA Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Artiva Biotherapeutics	N/A	N/A	-$83.86M	-$3.30	N/A

In the previous week, TuHURA Biosciences had 12 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Artiva Biotherapeutics. TuHURA Biosciences' average media sentiment score of 0.56 beat Artiva Biotherapeutics' score of 0.42 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Artiva Biotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics' return on equity of -53.86% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

TuHURA Biosciences has a beta of -0.01, suggesting that its stock price is 101% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market.

0.6% of TuHURA Biosciences shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

TuHURA Biosciences beats Artiva Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Prime Medicine?

TuHURA Biosciences (NASDAQ:HURA) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

In the previous week, TuHURA Biosciences had 12 more articles in the media than Prime Medicine. MarketBeat recorded 17 mentions for TuHURA Biosciences and 5 mentions for Prime Medicine. Prime Medicine's average media sentiment score of 0.90 beat TuHURA Biosciences' score of 0.56 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Prime Medicine	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has a beta of -0.01, meaning that its share price is 101% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,613.11%. TuHURA Biosciences' return on equity of -156.47% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.47%	-106.98%
Prime Medicine	-4,613.11%	-188.27%	-59.11%

TuHURA Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 317.63%. Prime Medicine has a consensus price target of $7.69, suggesting a potential upside of 132.81%. Given TuHURA Biosciences' higher probable upside, equities research analysts clearly believe TuHURA Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

TuHURA Biosciences has higher earnings, but lower revenue than Prime Medicine. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A
Prime Medicine	$4.63M	129.47	-$201.14M	-$1.06	N/A

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Prime Medicine beats TuHURA Biosciences on 10 of the 16 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$137.34M	$3.99B	$7.29B	$12.73B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.99	11.76	271.37	24.13
Price / Sales	N/A	1,299.21	605.97	78.27
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	6.34	17.27	11.19	6.40
Net Income	-$30.05M	-$22.72M	$3.46B	$348.39M
7 Day Performance	-5.48%	2.96%	2.07%	1.09%
1 Month Performance	2.13%	9.80%	7.40%	5.27%
1 Year Performance	-33.69%	54.94%	24.84%	16.29%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	1.815 of 5 stars	$2.16 +7.8%	$9.00 +317.6%	-38.5%	$137.34M	N/A	N/A	N/A	News Coverage Analyst Revision Gap Up
ARVN Arvinas	3.0938 of 5 stars	$9.16 -0.4%	$14.17 +54.7%	+27.9%	$590.75M	$316.70M	91.57	420
ALT Altimmune	2.7733 of 5 stars	$2.99 -0.5%	$14.33 +380.2%	-12.1%	$580.51M	$31K	N/A	50
EIKN Eikon Therapeutics	2.1523 of 5 stars	$10.79 +3.0%	$25.00 +131.7%	N/A	$578.27M	N/A	N/A	384	Analyst Forecast
ARTV Artiva Biotherapeutics	2.5939 of 5 stars	$11.64 -0.9%	$39.00 +235.2%	+279.5%	$569.62M	N/A	N/A	81

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. ARVN, ALT, EIKN, ARTV, and PRME

How does TuHURA Biosciences compare to Arvinas?

Summary

How does TuHURA Biosciences compare to Altimmune?

Summary

How does TuHURA Biosciences compare to Eikon Therapeutics?

Summary

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

Summary

How does TuHURA Biosciences compare to Prime Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. ARVN, ALT, EIKN, ARTV, and PRME

How does TuHURA Biosciences compare to Arvinas?

Which has better earnings & valuation, HURA or ARVN?

Is HURA or ARVN more profitable?

Do institutionals & insiders believe in HURA or ARVN?

Which has more volatility & risk, HURA or ARVN?

Does the media refer more to HURA or ARVN?

Do analysts rate HURA or ARVN?

Summary

How does TuHURA Biosciences compare to Altimmune?

Do insiders and institutionals hold more shares of ALT or HURA?

Is ALT or HURA more profitable?

Does the media prefer ALT or HURA?

Which has stronger earnings and valuation, ALT or HURA?

Do analysts prefer ALT or HURA?

Which has more risk & volatility, ALT or HURA?

Summary

How does TuHURA Biosciences compare to Eikon Therapeutics?

Which has higher earnings & valuation, EIKN or HURA?

Do analysts prefer EIKN or HURA?

Do institutionals and insiders hold more shares of EIKN or HURA?

Is EIKN or HURA more profitable?

Does the media prefer EIKN or HURA?

Summary

How does TuHURA Biosciences compare to Artiva Biotherapeutics?

Do analysts recommend HURA or ARTV?

Which has higher earnings & valuation, HURA or ARTV?

Does the media refer more to HURA or ARTV?

Is HURA or ARTV more profitable?

Which has more risk & volatility, HURA or ARTV?

Do insiders & institutionals have more ownership in HURA or ARTV?

Summary

How does TuHURA Biosciences compare to Prime Medicine?

Does the media refer more to HURA or PRME?

Which has more volatility and risk, HURA or PRME?

Is HURA or PRME more profitable?

Do analysts recommend HURA or PRME?

Which has stronger earnings and valuation, HURA or PRME?

Do insiders & institutionals have more ownership in HURA or PRME?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools